Food allergy
Food-allergy drops: the La Crosse Method protocol
Food-allergy drops are sublingual immunotherapy (SLIT) for foods: a tiny, precisely measured amount of the food allergen placed under the tongue every day, increased step by step so the immune system learns to tolerate more. Allergychoices has provided food-allergy SLIT for over 50,000 patients using the La Crosse Method Protocol, which treats several foods — and environmental allergies — in one daily routine.
Key points
- For children and adults with IgE-mediated food allergy confirmed by history and allergy testing.
- Dosing starts well below the amount that triggers a reaction and is raised gradually as testing and tolerance allow; three doses a day from a metered pump.
- The main goal is protection against accidental exposure. Eating a food on purpose comes only after a supervised food challenge.
- Avoidance and an epinephrine auto-injector stay part of the plan until your provider tells you otherwise.
- Peanut SLIT trials at the University of North Carolina found clinically meaningful desensitization in most children, with mostly mild, brief mouth itching.
Who food-allergy drops are for
Food-allergy drops treat IgE-mediated food allergy — the type that causes hives, swelling, vomiting, wheezing or anaphylaxis soon after eating a food. The diagnosis comes from your history together with skin or blood testing, and the treatment level is set from those results. Both children and adults are treated.
Most people with food allergy react to more than one food, and many also have environmental allergies such as dust mite or pollen. The La Crosse Method treats multiple foods in one prescription and is most often prescribed alongside environmental allergy drops, so one daily routine covers the whole allergic picture.
- Common foods treated: peanut, tree nuts, milk, egg, wheat, soy, fish, shellfish and sesame.
- Severity is not a barrier on its own. For people with mild to moderate allergy, reintroducing a food may be a realistic goal; for people with severe or life-threatening allergy, the goal is to lower the risk of a serious reaction after an accidental exposure.
How the La Crosse Method food protocol works
Treatment is built for one patient at a time. Your provider uses your test results, history and exam to choose the foods and the starting strength — an amount far below what triggers a reaction, yet enough for the tissue under the tongue to begin building tolerance. That tissue is rich in the dendritic cells that steer the immune system toward tolerance, which is why food drops are held under the tongue rather than simply eaten.
- Starting dose: set from your skin or blood test results, well below your reaction threshold.
- Daily routine: three doses a day from a metered pump bottle. Food and environmental drops can be taken at the same time.
- Build-up: strength is increased gradually as follow-up testing shows improvement and as you tolerate each step without symptoms.
- Maintenance: once the target strength is reached, the same daily routine continues to keep tolerance in place.
- Supply: each prescription is a 90-day supply in a glycerin base that keeps the drops stable at room temperature — no refrigeration needed.
- Duration: commonly three to five years for mild to moderate allergy; more severe food allergy usually takes longer.
- Allergychoices — Food Allergy Treatment (La Crosse Method)
- Allergychoices — How to Take Your Allergy Drops
- Allergychoices — The La Crosse Method Difference
- Theodoropoulou LM, Cullen NA. Sublingual immunotherapy for allergy to shrimp: the nine-year clinical experience of a Midwest Allergy-Immunology practice. Allergy Asthma Clin Immunol 2024
What treatment aims to achieve
The first aim for nearly every patient is protection: raising the amount of a food it takes to cause a reaction, so that a hidden ingredient or a mistake at a restaurant is far less likely to become an emergency.
Some patients go further and add a food back into their diet. That step is never taken at home on your own: your provider first confirms how much you tolerate with a supervised oral food challenge, then gives you a written plan. Until then — and often afterwards — you keep avoiding the food and keep an epinephrine auto-injector with you. Food drops add protection; they do not replace your emergency plan.
Who must be seen in person first
Every food-allergy treatment plan starts with an in-person evaluation by a provider trained in food allergy, who confirms the diagnosis and writes your emergency plan. Some people need a fuller in-office or specialist assessment before drops are started:
- Anyone with a history of anaphylaxis.
- Asthma that is severe or not well controlled.
- Eosinophilic esophagitis (EoE).
- Pregnancy — immunotherapy is not started during pregnancy.
- Infants and young children, whose first evaluation and any food challenge are done in the office.
- Anyone who cannot use an epinephrine auto-injector or who takes a beta-blocker.
What the evidence shows
The strongest controlled evidence for food SLIT comes from peanut trials led by Edwin Kim, MD, and colleagues at the University of North Carolina with NIH funding. Their 2024 randomized, placebo-controlled trial in toddlers is the clearest result: most children treated from age 1–4 became desensitized, and nearly half kept that protection after stopping treatment.
Scroll the table sideways to read every column.
| Study | Who took part | Treatment | Main result |
|---|---|---|---|
| Kim et al., J Allergy Clin Immunol 2011 — randomized, placebo-controlled (Duke) | 18 children aged 1–11 who completed treatment | 12 months of peanut SLIT or placebo | At the food challenge, treated children safely ate a median 1,710 mg of peanut protein vs 85 mg on placebo — 20 times more. |
| Kim et al., J Allergy Clin Immunol 2019 — long-term study (UNC) | 48 children aged 1–11 | 2 mg peanut protein a day for up to 5 years | 67% ate 750 mg or more at the challenge and 25% passed the full 5,000 mg. Side effects with 4.8% of doses, mostly brief mouth itching; no epinephrine needed for dosing. |
| Kim et al., J Allergy Clin Immunol 2023 — open-label study (UNC) | 54 children aged 1–11 | 4 mg a day for 48 months | 70% reached clinically significant desensitization (more than 800 mg) and 36% passed the full 5,000 mg. Reactions with a median 0.5% of doses; none required epinephrine. |
| Kim et al., J Allergy Clin Immunol 2024 — randomized, placebo-controlled (UNC, UT Southwestern) | 50 children aged 1–4 | 4 mg a day or placebo for 36 months | 60% vs 0% passed the 36-month challenge; 48% vs 0% stayed protected after 3 months off treatment. The youngest children did best. |
| Narisety et al., J Allergy Clin Immunol 2015 — randomized SLIT vs oral immunotherapy (Johns Hopkins) | 21 children aged 7–13 | Peanut SLIT or peanut oral immunotherapy (OIT) | OIT raised the reaction threshold more; SLIT caused significantly fewer adverse reactions. The two fit different patients. |
| Theodoropoulou & Cullen, Allergy Asthma Clin Immunol 2024 — 9-year clinical experience (Allergy Associates of La Crosse) | 66 patients with shrimp allergy | Started at 64–320 ng per dose, built up to 0.5 mg three times a day (average 51 months) | Of 18 patients who took an oral challenge, 61% tolerated 42 g of shrimp or more; no systemic reactions and no epinephrine at challenge. |
- The UNC trials studied single-food peanut SLIT at fixed research doses. La Crosse Method prescriptions are patient-specific and often combine several foods; the clinical experience behind them is documented by Allergy Associates of La Crosse, including the shrimp study above.
- La Crosse Method author D. L. Morris published on sublingual antigen for the diagnosis and treatment of food allergy in 1969, one of the earliest papers on the approach.
- Kim EH et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 2011
- Kim EH et al. Long-term sublingual immunotherapy for peanut allergy in children. J Allergy Clin Immunol 2019
- Kim EH et al. Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children. J Allergy Clin Immunol 2023
- Kim EH et al. Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children. J Allergy Clin Immunol 2024
- Narisety SD et al. Sublingual versus oral immunotherapy for peanut allergy: randomized, double-blind pilot study. J Allergy Clin Immunol 2015
- Theodoropoulou LM, Cullen NA. Sublingual immunotherapy for allergy to shrimp: the nine-year clinical experience of a Midwest Allergy-Immunology practice. Allergy Asthma Clin Immunol 2024
- Morris DL. Use of sublingual antigen in diagnosis and treatment of food allergy. Ann Allergy 1969
Frequently asked questions
Can allergy drops treat peanut, milk or egg allergy?
Yes — food-allergy drops are prescribed for peanut, tree nut, milk, egg, wheat, soy, fish, shellfish and sesame allergy, often several foods at once. Peanut has the most published research: in a randomized trial of children aged 1–4, 60% of those on peanut SLIT passed a food challenge after three years compared with none on placebo.
Can I stop carrying epinephrine once I start drops?
No. Keep your epinephrine auto-injector and keep avoiding the food until your provider has confirmed your tolerance with a supervised food challenge and changed your plan in writing. Food drops are designed to add protection against accidental exposure, not to replace your emergency plan.
How are food drops different from oral immunotherapy (OIT)?
OIT is swallowed and uses much larger daily amounts of food protein; Palforzia is an FDA-approved peanut OIT product. SLIT uses far smaller amounts held under the tongue. In the Johns Hopkins head-to-head pilot, OIT raised the reaction threshold more while SLIT caused significantly fewer adverse reactions — the right choice depends on the patient.
How long does food-allergy treatment take?
A common range is three to five years for mild to moderate food allergy, with more severe food allergy usually taking longer. Each prescription is a 90-day supply, and strength is adjusted between refills as testing and tolerance improve.
Do food-allergy drops need to be refrigerated?
No. La Crosse Method drops are made in a glycerin base that keeps the allergens stable at room temperature, so they travel easily to school, work or on vacation.
Are side effects common?
Side effects are usually mild and local — most often brief itching in the mouth. In the UNC long-term peanut study, side effects occurred with 4.8% of doses and none of the dosing reactions needed epinephrine. Your provider explains what to watch for and what to do.
Regulatory status
A small number of sublingual immunotherapy (SLIT) tablets are FDA-approved for specific allergens. Personalized allergy drops are compounded by a pharmacy for each patient and prescribed off-label — a long-standing, legitimate practice with decades of use, and SLIT is a first-line prescription approach in much of Europe. Compounded allergy drops are not FDA-approved, but they are created using FDA-approved allergenic extracts, the same as in allergy shots. Off-label does not mean unsafe or experimental.
Related reading
Sources
- Allergychoices — Food Allergy Treatment (La Crosse Method)
- Allergychoices — Food Allergies
- Allergychoices — How to Take Your Allergy Drops
- Allergychoices — The La Crosse Method Difference
- Kim EH et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 2011 (PMID 21281959) — Randomized, placebo-controlled; 18 children.
- Kim EH et al. Long-term sublingual immunotherapy for peanut allergy in children. J Allergy Clin Immunol 2019 (PMID 31493887) — Extended maintenance up to 5 years; 48 children.
- Kim EH et al. Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children. J Allergy Clin Immunol 2023 (PMID 36828080) — Open-label, 48 months; 54 children.
- Kim EH et al. Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children. J Allergy Clin Immunol 2024 (PMID 37815782) — Randomized, placebo-controlled; 50 children aged 1–4.
- Narisety SD et al. Sublingual versus oral immunotherapy for peanut allergy: randomized, double-blind pilot study. J Allergy Clin Immunol 2015 (PMID 25528358)
- Theodoropoulou LM, Cullen NA. Sublingual immunotherapy for allergy to shrimp: the nine-year clinical experience of a Midwest Allergy-Immunology practice. Allergy Asthma Clin Immunol 2024 (PMID 38734651) — Allergy Associates of La Crosse; retrospective chart review.
- Morris DL. Use of sublingual antigen in diagnosis and treatment of food allergy. Ann Allergy 1969 (PMID 5785921)
- Gurgel RK et al. Clinical Practice Guideline: Immunotherapy for Inhalant Allergy — executive summary (2024) — Patient-selection precautions for starting immunotherapy.
- FDA — Palforzia (peanut allergen powder)
